



## Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 7, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 7, 2024-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the Oppenheimer 34<sup>th</sup> Annual Healthcare Life Sciences Conference, a virtual event, on Wednesday, February 14, 2024 beginning at 10:40 a.m. Eastern Time.

A live webcast of the presentation will be accessible on the Events page under the News & Events heading of Quince's Investor Relations website at [ir.quincetx.com](http://ir.quincetx.com). An archive of the webcast will be available shortly following the end of the live event.

### About Quince Therapeutics

Quince Therapeutics (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the potential of a patient's own biology to deliver innovative and life-changing therapeutics to those living with rare diseases. For more information on the company and its latest news, visit [www.quincetx.com](http://www.quincetx.com) and follow Quince Therapeutics on social media platforms [LinkedIn](#), [Facebook](#), and [Twitter/X](#).

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20240207118051/en/>

### Media & Investor Contact:

Stacy Roughan  
Quince Therapeutics, Inc.  
Vice President, Corporate Communications & Investor Relations  
[ir@quincetx.com](mailto:ir@quincetx.com)

Source: Quince Therapeutics, Inc.